LONDON--(BUSINESS WIRE)--Mar. 31, 2017--
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a
market-leading medical technology and innovation company, today
announced it is reiterating its full-year 2017 guidance published on
March 1, 2017, and the company undertakes no duty to update for
subsequent events.
LivaNova expects worldwide net sales for full-year 2017 to grow between
1 and 3 percent on a constant-currency basis. Adjusted diluted earnings
per share for 2017 are expected to be in the range of $3.25 to $3.45.
About LivaNova
LivaNova PLC is a global medical technology company built on nearly five
decades of experience and a relentless commitment to improve the lives
of patients around the world. LivaNova’s advanced technologies and
breakthrough treatments provide meaningful solutions for the benefit of
patients, healthcare professionals and healthcare systems. Headquartered
in London and with a presence in more than 100 countries worldwide, the
company employs more than 4,500 employees. LivaNova operates as three
business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm
Management, with operating headquarters in Mirandola
(Italy), Houston (U.S.A.) and Clamart (France), respectively.
For more information, please visit www.LivaNova.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170331005817/en/
Source: LivaNova PLC
LivaNova PLC Investor Relations and Media
Karen King, +1-281-228-7262
Vice
President, Investor Relations & Corporate Communications
or
Deanna
Wilke, +1-281-727-2764
Corporate External Communications Manager
Corporate.Communications@LivaNova.com